-3.21%
-12.31%
-18.18%
-10.00%
72.96%
-73.56%
-58.96%
AI Spotlight on PPGN
Company Description
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide.It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products.It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies.
The company is also involved in manufacturing peptides for commercially approved peptide therapeutics.In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides.Further, the company offers regulatory affair support services.
The company was founded in 1952 and is headquartered in Zug, Switzerland.PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Market Data
| Last Price | 25.65 |
| Change Percentage | -3.21% |
| Open | 26.4 |
| Previous Close | 26.5 |
| Market Cap ( Millions) | 846 |
| Volume | 17419 |
| Year High | 35.8 |
| Year Low | 14.56 |
| M A 50 | 27.67 |
| M A 200 | 29.99 |
Financial Ratios
| FCF Yield | -2.26% |
| Dividend Yield | 0.00% |
| ROE | -12.81% |
| Debt / Equity | 29.81% |
| Net Debt / EBIDTA | -81.06% |
| Price To Book | 2.35 |
| Price Earnings Ratio | -17.4 |
| Price To FCF | -44.27 |
| Price To sales | 2.8 |
| EV / EBITDA | -41.28 |
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Custom Projects
Expected Growth : 8 %
What the company do ?
Custom Projects from PolyPeptide Group AG refers to tailored peptide-based solutions for pharmaceutical and biotech companies, offering bespoke development and manufacturing services.
Why we expect these perspectives ?
PolyPeptide Group AG's Custom Projects segment growth is driven by increasing demand for complex peptides, strategic partnerships, and expansion into new therapeutic areas. The company's expertise in peptide synthesis, strong regulatory compliance, and investments in R&D also contribute to its growth. Additionally, the rising need for personalized medicine and targeted therapies fuels demand for custom peptides, supporting the segment's 8% growth.
Segment n°2 -> Contract Manufacturing
Expected Growth : 9 %
What the company do ?
Contract Manufacturing from PolyPeptide Group AG refers to the outsourcing of peptide manufacturing to a third-party company, ensuring high-quality products while reducing costs and increasing efficiency.
Why we expect these perspectives ?
PolyPeptide Group AG's 9% growth in Contract Manufacturing is driven by increasing demand for complex peptides and antibodies in pharmaceutical and biotech industries, coupled with the company's expansion into new markets, strategic partnerships, and investments in capacity expansion and technology upgrades, enabling it to capitalize on the growing outsourcing trend in the industry.
Segment n°3 -> Generics and Cosmetics
Expected Growth : 11 %
What the company do ?
Generics and Cosmetics is a segment of PolyPeptide Group AG that develops and manufactures peptides for cosmetic and generic pharmaceutical applications.
Why we expect these perspectives ?
PolyPeptide Group AG's Generics and Cosmetics segment growth of 11% is driven by increasing demand for affordable generic peptides, expansion into new markets, and strategic partnerships. Additionally, growing consumer preference for natural and organic cosmetics, coupled with the company's innovative product offerings, contribute to the segment's rapid growth.
Polypeptide Group Ag Products
| Product Range | What is it ? |
|---|---|
| Peptides | PolyPeptide Group AG offers a wide range of peptides, including generic and custom peptides, for use in pharmaceutical, cosmetic, and biotechnological applications. |
| Proteins | The company provides a variety of proteins, including recombinant proteins, for use in pharmaceutical, biotechnological, and diagnostic applications. |
| Amino Acids | PolyPeptide Group AG offers a range of amino acids, including essential and non-essential amino acids, for use in pharmaceutical, cosmetic, and nutritional applications. |
| Custom Synthesis | The company provides custom synthesis services for peptides, proteins, and amino acids, tailored to meet the specific needs of clients. |
| Process Development | PolyPeptide Group AG offers process development services to optimize the production of peptides, proteins, and amino acids. |
| Analytical Services | The company provides analytical services, including HPLC, MS, and NMR, to support the development and production of peptides, proteins, and amino acids. |
PolyPeptide Group AG's Porter Forces
Threat Of Substitutes
The threat of substitutes for PolyPeptide Group AG is moderate, as there are some alternatives available in the market, but they are not very attractive to customers.
Bargaining Power Of Customers
The bargaining power of customers is low, as PolyPeptide Group AG has a strong brand image and customers are loyal to the brand.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate, as PolyPeptide Group AG has a diverse supplier base, but some suppliers have a higher bargaining power due to their size and importance.
Threat Of New Entrants
The threat of new entrants is high, as the biotechnology industry is attractive and there are many companies interested in entering the market.
Intensity Of Rivalry
The intensity of rivalry is high, as there are many competitors in the biotechnology industry, and PolyPeptide Group AG faces intense competition from other companies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 22.97% |
| Debt Cost | 5.60% |
| Equity Weight | 77.03% |
| Equity Cost | 9.11% |
| WACC | 8.31% |
| Leverage | 29.81% |
PolyPeptide Group AG : Quality Control
PolyPeptide Group AG passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PSG.DE | PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream … |
| PHN.MI | Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The … |
| INCR | InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis … |
| BMK.L | Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that supports the development of food and farming industries in the United Kingdom, Norway, the Faroe … |
| RJF.MC | Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Reig Jofre
A-Score
1-Year Total Return ->
🥈
PharmaSGP Holding
A-Score
1-Year Total Return ->
🥉
Pharmanutra
A-Score
1-Year Total Return ->
4
PolyPeptide
A-Score
1-Year Total Return ->
5
Benchmark
A-Score
1-Year Total Return ->
6
